Information Collection Request

FDA Approval to Market a New Drug

ICR 201502-0910-008 · OMB 0910-0001 · Historical Active

Forms and Documents
DocumentTypeStatusAvailability
Form 3331 314.50 (a), (b), (c), (d), (e), (f), and (k) Form and Instruction Unchanged Available
Justification Memo for 83C Change Request 2-24-15.doc Justification for No Material/Nonsubstantive Change Uploaded 2015-02-24 Available
SUPPORTING STATEMENT 0001 FINAL 9-10-14.doc Supporting Statement A Uploaded 2014-09-10 Available
IC Document Collections
IC IDCollectionTypeStatusForm
5662 314.50 (a), (b), (c), (d), (e), (f), and (k) Form and Instruction Unchanged
184606 314.550 Unchanged
184605 314.420 Unchanged
184604 314.101(a) Unchanged
184603 314.99(a) Unchanged
184602 314.97 Unchanged
184601 314.96 Unchanged
184600 314.94(a) and (d) Unchanged
184599 314.81(b)(3)(i) [2253] Unchanged
184598 314.81(b)(2) [2252] Unchanged
184597 314.81(b)(1) [3331] Unchanged
184596 314.72 Unchanged
184595 314.70 and 314.71 Unchanged
184594 314.65 Unchanged
184593 314.60 Unchanged
184592 314.95 Unchanged
184591 314.52 Unchanged
ICR Details
0910-0001 201502-0910-008
Historical Active 201412-0910-015
HHS/FDA CDER
FDA Approval to Market a New Drug
No material or nonsubstantive change to a currently approved collection   No
Regular
Approved without change 03/16/2015
Retrieve Notice of Action (NOA) 02/26/2015
  Inventory as of this Action Requested Previously Approved
12/31/2017 12/31/2017 12/31/2017
85,745 0 85,745
3,421,306 0 3,421,306
0 0 0

Section 505 of the FD&C Act requires that a new drug may not be marketed unless the manufacturer provides FDA with scientific evidence that the drug is both safe and effective. The regulations at 21 CFR part 314 provide the means through which pharmaceutical manufacturers can obtain FDA approval of a drug product marketing application, and the means through which FDA can assure the safety and effectiveness of marketed drug products. Without the information provided by industry on the drug products they seek to market, FDA would not be able to assure the safety and effectiveness of marketed drug products.

US Code: 21 USC 355(a) Name of Law: Federal Food, Drug, and Cosmetic Act
  
None

Not associated with rulemaking

  79 FR 16003 03/24/2014
79 FR 55801 09/17/2014
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 85,745 85,745 0 0 0 0
Annual Time Burden (Hours) 3,421,306 3,421,306 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$146,125,000
No
No
No
No
No
Uncollected
Ila Mizrachi 301 796-7726 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
02/26/2015